Atossa Genetics Inc. (NASDAQ:ATOS) reported that its preliminary Phase 2 Study achieved its primary endpoint for the topical Endoxifen that rapidly reduces breast density.
Atossa
Genetics Inc. (NASDAQ:ATOS), a Healthcare sector firm, traded 14.95 Million
shares in last trading session with closing price of $2.58 per share. Stock
value has moved between $0.8 – 7.37 in last one year. Analyst’s mean target
price for Atossa Genetics Inc. (NASDAQ:ATOS) is $9.00. ATOS EPS growth this
year is 49.80%.
Seelos Therapeutics, Inc. (NASDAQ:SEEL) acquired the license of gene therapy
program to address Parkinson’s disease from Duke University. The gene therapy
program targets the regulation of the SNCA gene. Seelos plans to study this
approach, named SLS-004, initially in Parkinson’s disease.
On
last trading day, Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares closed at
$2.32 per share. SEEL market capitalization is 47.84 with beta of 0.79.
Analyst’s mean target price for Seelos Therapeutics, Inc. (NASDAQ:SEEL) is
$6.00 whereas analysts mean recommendation is 2.00. Its weekly performance is
5.45% while year to date (YTD) performance is -59.72%.
Zogenix, Inc. (NASDAQ:ZGNX) reported an FDA deal to proceed with the
resubmission of its FINTEPLA new drug application.
In
last session Zogenix, Inc. (NASDAQ:ZGNX) traded 4.77 Million shares and was
closed at $47.65. Analyst’s mean target price for ZGNX is $57.09 while analysts
mean recommendation is 1.70. Company is -24.06% away from its 52 week high and
is moving 42.54% ahead of its 52 week low. ZGNX return on assets is -22.00%.
Zogenix, Inc. (NASDAQ:ZGNX) quarterly performance is -12.63%.
Evoke Pharma, Inc. (NASDAQ:EVOK) requested a Type A FDA meeting to plan for the
resubmission of Gimoti NDA.
Evoke Pharma, Inc. (NASDAQ:EVOK), a Healthcare sector
firm, traded 3.75 Million shares on last trading day with closing price of
$0.57 per share. Stock value has moved between $0.5 – 3.35 in last one year.
Analyst’s mean target price for Evoke Pharma, Inc. (NASDAQ:EVOK) is $8.00 while
analysts mean recommendation is 2.50. EVOK EPS growth this year is 44.50%.
